What you should know about PR3-ANCA: Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA by Specks, Ulrich
Review
What you should know about PR3-ANCA
Conformational requirements of proteinase 3 (PR3) for
enzymatic activity and recognition by PR3-ANCA
Ulrich Specks
Mayo Clinic and Foundation, Rochester, Minnesota, USA
Abstract
The neutrophil azurophil granule constituent proteinase 3 (PR3) is the principal antigen for
anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener’s granulomatosis. The
conformation of the mature PR3 enzyme results from intracellular post-translational
processing. The nascent molecule undergoes proteolytic cleavage of the amino-terminal
signal peptide and activation dipeptide and of a carboxy-terminal peptide extension. The
conformation of PR3 is stabilized by four disulfide bonds and, to a lesser extent, by
asparagine-linked glycosylation. Most anti-neutrophil cytoplasmic antibodies directed against
proteinase 3 (PR3-ANCA) recognize conformational epitopes. The expression of recombinant
PR3 has provided a better understanding of the significance of the various intracellular
processing steps for enzymatic activity and recognition by PR3-ANCA.
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ANCA = anti-neutrophil cytoplasmic antibodies; a1-PI = a1-proteinase inhibitor; C1 = complement factor 1; ELISA = enzyme-linked
immunosorbent assay; HMC = human mast cell; HMC-1/PR3-S176A cells = HMC-1 cells expressing rPR3-S176A; IL-1b, interleukin 1-b; IL-8
= interleukin 8; NADPH = nicotinamide adenine dinucleotide phosphate; PR3 = proteinase 3; PR3-ANCA = anti-neutrophil cytoplasmic anti-
bodies directed against proteinase 3; rPR3 = recombinant PR3; rPR3-S176A = rPR3 with the substitution of the serine 176 residue with
alanine; D-rPR3-S176A = amino-terminally processed rPR3-S176A expressed in 293 cells; TGF-b = transforming growth factor-b; TNF-a =
tumor necrosis factor-a.
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PR3-ANCA have been implicated in the pathogenesis of
vasculitis [1,2], and direct functional interactions of PR3-
ANCA with the PR3 molecule have been described [3–5].
Some PR3-ANCA can interfere with the complexation of
PR3 with its natural inhibitor, a1-proteinase inhibitor (a1-
PI), while others can directly inhibit the enzymatic activity
of PR3. These observations suggest that different PR3-
ANCA subsets bind to different epitopes on the PR3 mol-
ecule with potentially opposing functional implications.
Competition studies of PR3-ANCA with anti-PR3 mono-
clonal antibodies further indicate that PR3-ANCA from
patients are directed against a restricted number of differ-
ent epitopes on PR3 [6]. Consequently, to better under-
stand the pathogenic potential of PR3-ANCA we must
delineate the heterogeneous interactions of PR3-ANCA
with its target antigen by identifying the specific epitopes
reactive with PR3-ANCA and the functional impact of
binding of PR3-ANCA to these specific epitopes.
Most of the biological functions ascribed to PR3 are
dependent on its proteolytic activity. The expression of
PR3 on the surface of activated neutrophils [7] and its
enzymatic substrates, which include basement membrane
proteins [8], suggests that PR3 may facilitate the migrationArthritis Research    Vol 2 No 4 Specks
of neutrophils to tissue sites of inflammation. The prote-
olytic activity of PR3 has also been implicated in modulat-
ing the activity of platelets and endothelial cells [9] and of
inflammatory mediators such as complement factor 1 (C1)
inhibitor [10], IL-8 [11], tumor necrosis factor (TNF)-a
[12,13], IL-1b [13], or transforming growth factor (TGF)-b
[14]. On the other hand, some potential biological activi-
ties of PR3, such as its bactericidal activity [15], the
induction of IL-8 secretion from endothelial cells [16], and
the blockade of neutrophil NADPH oxidase activation [17],
appear to be independent of its proteolytic activity, sug-
gesting that they are mediated by other structural domains
of the molecule.
The physiological and pathogenic functions of PR3 are
clearly determined by its ability to bind to other molecules,
such as specific substrates for proteolytic cleavage, spe-
cific enzyme inhibitors, or PR3-ANCA. These molecular
interactions depend on the intact conformation of various
structural domains of PR3. The final conformation of
mature PR3 is stabilized by four disulfide bonds and
appropriate asparagine-linked glycosylation, and it requires
the cleavage of the amino-terminal activation dipeptide
[18,19] (Fig. 1). The significance of carboxy-terminal pro-
cessing of PR3 is less well defined [20•]. Like lymphocyte
granzymes and the other neutrophil serine proteases elas-
tase and cathepsin G, PR3 undergoes several proteolytic
processing steps [18,19,20•]. PR3 is synthesized as a
preproenzyme. After cleavage of the signal peptide and
leaving the endoplasmic reticulum, the nascent PR3 mole-
cule still carries an amino-terminal activation dipeptide,
which maintains the proenzyme in its inactive conformation
[20•]. Subsequent cleavage of this amino-terminal propep-
tide allows insertion of the freed amino-terminus into the
interior of the molecule, where it interacts with the aspartic
acid residue adjacent to the serine of the active site. This
renders the active-site pocket of the enzyme accessible to
substrates [21•]. In the azurophil granules of neutrophils,
PR3 is stored in its amino-terminally processed, enzymati-
cally active form [22].
Research in the expression of recombinant PR3 (rPR3) has
been driven by several quests: that to obtain abundant
amounts of purified target antigen for sensitive and specific
solid-phase assay systems allowing reliable detection and
quantification of PR3-ANCA in sera of patients; the quest
to allow modifications of the molecule for the study of intra-
cellular processing and structure–function relationships of
PR3; and the quest to allow the identification of epitopes
recognized by PR3-ANCA. To these ends, rPR3 has been
expressed using bacterial (Escherichia coli) [23,24], yeast
(Pichia pastoris) [24], baculovirus (SfF9 cells) [21•,25,26],
and mammalian (HMC-1, RBL-1, 32D, and 293 cells)
expression systems [27–29]. These investigations have
provided valuable insights about the intracellular process-
ing of PR3 and its effects on the structure of PR3 and
about the conformational nature of PR3-ANCA epitopes.
Bini and coworkers first demonstrated that most human
PR3-ANCA recognize conformational epitopes [23]. More
than half of PR3-ANCA that have been boiled in sodium
dodecyl sulfate no longer recognize PR3 in Western blots.
Reduction of PR3 completely abolished the recognition by
more than 90% of PR3-ANCA [23]. Exposure of PR3 to
conditions that only partially denature the protein, such as
low pH, is also sufficient to destroy PR3 antigenicity [23].
Furthermore, a recombinant PR3 (rPR3) fusion protein
expressed in E. coli that did not contain the amino-terminal
PR3 signal peptide or the activation dipeptide sequence
(thus coding for mature PR3) was not recognized by PR3-
ANCA, and neither was an in vitro translation product of
rPR3 that contained the reducing agent dithiothreitol [23].
Thus, intact disulfide bonds are crucial for PR3’s anti-
genicity. Other post-translational modifications of native
PR3 not occurring in E. coli may also be prerequisites for
proper recognition by PR3-ANCA. Another rPR3 product
expressed in E. coli was also not recognized by PR3-
ANCA [24]: this particular variant did contain the amino-
terminal propeptide extension. When the same construct
was expressed in the yeast P. pastoris, the expressed
rPR3 product was recognized by 7 of 10 PR3-ANCA-pos-
itive sera when the rPR3 was used as target antigen in a
capture enzyme-linked immunosorbent assay (ELISA), but
only by 1 of 10 when it was used in a direct ELISA [24].
This suggests that not all conformational epitopes recog-
nized by PR3-ANCA are displayed on rPR3 expressed in
P. pastoris. Furthermore, the conformation of PR3-ANCA
epitopes appears more vulnerable to modifications caused
by the purification procedure or the binding to plastic than
that of epitopes of native neutrophil PR3.
Figure 1
Schematic diagram of the PR3 molecule. The light and dark gray bars
represent the amino-terminal signal peptide and activation dipeptide,
respectively. The mature enzyme is represented by the white bar, and
the carboxy-terminal peptide extension is represented by the black bar.
The cysteine residues forming the four disulfide bonds (horizontal
black lines) are shown as circled residues. The asparagine residues at
positions 102 and 147 represent two potential glycosylation sites. The
histidine-44, aspartic acid-91, and serine-176 residues make up the
active site. The single-letter code for amino acid residues is used.
Amino acids are numbered consecutively starting with the first residue
of the mature enzyme [20•]. The diagram is not drawn to scale.
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Using the baculovirus system, rPR3 has also been
expressed in insect cells [21•,25,26]. rPR3 expressed in
Sf9 cells assumes the conformation of the active enzyme
[21•] and is recognized by the majority of PR3-ANCA [30],
provided the amino-terminal activation dipeptide is
cleaved  in vitro after purification of the proenzyme. Disul-
fide bonds are formed appropriately in Sf9 cells. Other
post-translational modifications of rPR3 are either lacking
or inappropriate for the generation of the active enzyme
recognized by all PR3-ANCA [25,26]. The amino-terminal
propeptide is not cleaved intracellularly [21•], and
asparagine-linked glycosylation of rPR3 in Sf9 cells is dif-
ferent from that of PR3 purified from neutrophils [26]. The
majority of asparagine-linked glycosylation isoforms of
rPR3 from Sf9 cells have a molecular mass of 34 kDa,
whereas the majority of the native PR3 glycosylation iso-
forms purified from azurophil granules of neutrophils have
a mass of about 29 kDa [26]. In addition, in the reported
crystal structure of PR3, which is based on rPR3
expressed in Sf9 cells, only one of the two potential
asparagine-linked glycosylation sites appeared occupied
[21•], whereas both sites are used in rPR3 expressed in
hematopoietic cells and in native PR3 from neutrophils [31].
When rPR3 is expressed in hematopoietic cells, it is
processed to an active enzyme and stored in granules
[27,28]. All PR3-ANCA recognize rPR3 expressed in the
human mast cell line HMC-1 [32]. As indicated by
immunofluorescence and capture ELISA data, the affinity
of PR3-ANCA to HMC-1 cell rPR3 is similar to that of
neutrophil PR3 [32,33]. This similarity suggests that the
conformational epitopes recognized by PR3-ANCA are
fully accessible on rPR3 expressed in HMC-1 cells. Fur-
thermore, the recognition of rPR3 by PR3-ANCA is not
affected by the substitution of the active site serine by an
alanine residue (S176A), indicating that the conforma-
tional epitopes recognized by PR3-ANCA are not
affected by this mutation even though it alters the active
site sufficiently to render the molecule enzymatically inac-
tive [27,33]. This mutation subsequently allowed us to
express rPR3 variants in the epithelial cell line 293 [29].
The overwhelming majority of rPR3 expressed in 293
cells is secreted into the media supernatant in an
unprocessed form [29]. Two rPR3 variants representing
the amino-terminally unprocessed pro-form of PR3 (rPR3-
S176A) and the amino-terminally processed mature form
of PR3 (D-rPR3-S176A) were expressed in 293 cells
[29]. In the capture ELISA, PR3-ANCA recognize mature
rPR3 contained in HMC-1/PR3-S176A cells just as well
as they recognize that contained in media supernatants of
D-rPR3-S176A expressing 293 cells [29,33]. In contrast,
the proform variant of rPR3 is not recognized by all PR3-
ANCA [29]. While some PR3-ANCA sera show the same
reactivity with both mature and pro-rPR3, most of them
bind less well to pro-PR3 than to mature rPR3 [29]. This
indicates that some PR3-ANCA epitopes are equally
accessible on mature and pro-PR3, whereas other epi-
topes are less or not at all accessible on pro-PR3.
The clinical relevance of the differential recognition of
these rPR3 variants with different conformations is cur-
rently under investigation. Preliminary evidence obtained
using our capture ELISA suggests that the correlation of
clinical disease activity with PR3-ANCA reacting with pro-
PR3 is more readily apparent than that of the reactivity
with mature PR3 [34].
While preservation of proper disulfide bonds in the PR3
molecule is crucial for recognition of PR3-ANCA, and
more PR3-ANCA appear to recognize the mature form of
the enzyme than the amino-terminally unprocessed
proform, the carboxy-terminal processing and asparagine-
linked glycosylation appear less relevant. The fact that
rPR3 secreted into the 293 cell media supernatant is
carboxy-terminally unprocessed (my unpublished data)
implies that carboxy-terminal processing of PR3 has little
effect on the antigenicity of PR3 [29]. This interpretation
is supported by the observation that an rPR3 construct
carrying a C-terminal poly-histidine extension is recog-
nized just as well by PR3-ANCA as is rPR3 without this
extension [35].
Several lines of evidence suggest that asparagine-linked
glycosylation of PR3 does not significantly affect recogni-
tion of PR3-ANCA. Deglycosylated neutrophil PR3 is
recognized by PR3-ANCA serum and by the conformation-
sensitive monoclonal antibody WGM2 with the same affin-
ity as native PR3 purified from neutrophils [26]. When
expressed in hematopoietic cell lines or in 293 cells, rPR3
with large oligosaccharides is secreted into the media. In
contrast, the intracellularly retained rPR3 is not as heavily
glycosylated [27–29]. PR3-ANCA recognize the heavily
glycosylated rPR3 in 293 cell media supernatants as well
as the rPR3 stored in granules of HMC-1/PR3 cells and
as purified neutrophil PR3 [29,33]. Conversely, asparagine-
linked glycosylation mutants of rPR3 expressed in HMC-1
cells are recognized by PR3-ANCA [31]. Consequently,
even though the asparagine-linked glycosylation status of
PR3 affects the enzymatic activity and thermostability of
the molecule, it has little effect on the accessibility of con-
formational epitopes by PR3-ANCA [31].
Conclusion
The biological functions of PR3 and its recognition by PR3-
ANCA are defined by the molecule’s conformation. Its
exact conformation is the result of several intracellular post-
translational processing steps that appear to be largely
restricted to cells of hematopoietic lineage. Mammalian
expression systems for conformationally intact rPR3 repre-
sent very promising tools for the identification of specific
PR3-ANCA epitopes and will help to clarify existing contro-
versies about the nature of these epitopes [36,37].References
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